Education
About Us
Working with TipRanks
Follow Us
DiaSorin S.p.A. (IT:DIA)
:DIA
DIA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€88.96 - €112.35
Previous CloseN/A
Volume135.55K
Average Volume (3M)132.92K
Market Cap
€5.29B
Enterprise Value€5.76B
Total Cash (Recent Filing)€344.00M
Total Debt (Recent Filing)€962.00M
Price to Earnings (P/E)28.7
Beta0.60
Next Earnings
Jul 31, 2025EPS Estimate
1.15Next Dividend Ex-Date
May 19, 2025Dividend Yield1.21%
Share Statistics
EPS (TTM)1.17
Shares Outstanding55,948,257
10 Day Avg. Volume122,714
30 Day Avg. Volume132,919
Financial Highlights & Ratios
PEG Ratio-24.33
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio17.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€104.50Price Target Upside8.07% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
DiaSorin S.p.A. News
PremiumCompany Announcements
DiaSorin S.p.A. Boosts 2024 Revenue Guidance Amid Strong Growth
PremiumPre-Earnings
Is 0GZX a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDiaSorin reported 4Q results which were a slight beat vs Consensus on Topline and EBITDA, starting the year on a solid footing backdrop considered.
Growth OutlookManagement also pointed to ~25% combined yoy growth for the Verigene and LIAISON PLEX to around €75m, which implies low-teens growth for FY25 in Molecular Diagnostics for FY25, which serves as a solid departure point into FY25.
Investor ConfidenceFY25 Outlook should give investors some confidence.
Bears Say
Regional GrowthEuropean growth slowed to 4% CER, with US growing 15%, effectively normalising above average growth driven by high market share tests.
Revenue PerformanceDiaSorin (DIA) reported 4Q results which were a ~2% miss vs Consensus on Topline and EBITDA, but achieved FY24 guidance.
---
Options Prices
Currently, No data available
---
Ownership Overview
12.49% Insiders
6.02%
Mutual Funds
― Other Institutional Investors
77.57% Public Companies and
Individual Investors
DIA FAQ
What was DiaSorin S.p.A.’s price range in the past 12 months?
DiaSorin S.p.A. lowest stock price was €88.96 and its highest was €112.35 in the past 12 months.
What is DiaSorin S.p.A.’s market cap?
DiaSorin S.p.A.’s market cap is €5.29B.
When is DiaSorin S.p.A.’s upcoming earnings report date?
DiaSorin S.p.A.’s upcoming earnings report date is Jul 31, 2025 which is in 78 days.
How were DiaSorin S.p.A.’s earnings last quarter?
DiaSorin S.p.A. released its earnings results on May 06, 2025. The company reported €1.168 earnings per share for the quarter, beating the consensus estimate of €1.102 by €0.066.
Is DiaSorin S.p.A. overvalued?
According to Wall Street analysts DiaSorin S.p.A.’s price is currently Undervalued.
Does DiaSorin S.p.A. pay dividends?
DiaSorin S.p.A. pays a Annually dividend of €1.149 which represents an annual dividend yield of 1.21%. See more information on DiaSorin S.p.A. dividends here
What is DiaSorin S.p.A.’s EPS estimate?
DiaSorin S.p.A.’s EPS estimate is 1.15.
How many shares outstanding does DiaSorin S.p.A. have?
DiaSorin S.p.A. has 55,948,257 shares outstanding.
What happened to DiaSorin S.p.A.’s price movement after its last earnings report?
DiaSorin S.p.A. reported an EPS of €1.168 in its last earnings report, beating expectations of €1.102. Following the earnings report the stock price went down -1.986%.
Which hedge fund is a major shareholder of DiaSorin S.p.A.?
Currently, no hedge funds are holding shares in IT:DIA
---
Company Description
DiaSorin S.p.A.
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
---
DIA Stock 12 Month Forecast
Average Price Target
€104.50
▲(8.07% Upside)
Technical Analysis
---